Sermorelin for sale is a query that returns storefronts, and storefronts are graded on design rather than on disclosure. The listing is the only document you get before the card is charged, so it repays being read like a spec sheet rather than an advert. One real lot is used below as the worked example, including the places where its paperwork stops.
Key takeaways
- A listing that publishes a lot number is making a claim you can check. A listing that publishes a purity percentage with no lot behind it is making a claim you cannot.
- Lot 38-01260229 was analysed by MZ Biolabs on February 7, 2026 by HPLC-UV-MS: 99.79% purity, four detected peaks, and 11.31 mg measured against a 10 mg label.
- That certificate reports purity and quantity only. It carries no endotoxin test and no sterility test, which is the single most useful thing to notice before anything gets reconstituted.
- Sermorelin was a genuinely approved drug. Geref, NDA 020443, was approved September 26, 1997 and is now discontinued, with the FDA record stating the withdrawal was not for safety or effectiveness reasons.
- The approved evidence was paediatric growth hormone deficiency and pituitary diagnostics. PubMed returns zero papers for sermorelin and anti-aging, so any listing selling physique outcomes is running ahead of its literature.
The vendor we point lifters to
Sermorelin from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
The published certificate for lot 38-01260229 assays this vial at 11.31 mg against a 10 mg label, and reports purity and quantity only, with no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Lot certificate published, purity and quantity
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 6, 2026.
Sermorelin for sale: the fields a listing has to fill in
Every peptide storefront looks broadly the same. The differences sit in a small number of fields, and a listing either fills them or it does not.
| Field | What a real listing states | What a thin one does |
|---|---|---|
| Form | Lyophilised powder, sealed vial | Says "peptide" and moves on |
| Labelled quantity | 10 mg, printed on the vial and the page | A vague "high dose" or a range |
| Lot number | A specific string tied to the certificate | No lot, or a lot that appears on every product |
| Certificate | A dated PDF naming the testing lab and analyst | A cropped image of a purity number |
| Testing scope | Names what was tested and what was not | Implies the certificate covers everything |
| Storage | Cold, dark, sealed until reconstitution | Silent |
| Intended use | Laboratory use, stated plainly | Dosing charts and outcome promises |
| Price per mg | Derivable from the page in one division | Buried under bundle pricing |
None of these fields is difficult to publish. That is why the omissions are informative: a seller holding its own stock has the certificate on a hard drive and can attach it, while an intermediary has to go and ask for it.
The lot number is the whole thing
A purity figure without a lot number is a marketing statistic. It describes an unnamed batch tested on an unnamed date, which is to say it describes nothing you are being sold.
A lot number is different. It ties one number to one production run, and it lets you match the string on the certificate against the string printed on the vial that arrives. If those two do not match, the certificate is describing somebody else's material. That check takes about fifteen seconds and it is the only part of the buying process where a reader has genuine leverage.
The same logic applies to dates. A certificate from three years ago describes a batch that has almost certainly been exhausted. Testing scope, purity and measured content are all properties of a specific lot, not of a vendor or a product line, and the wording on a good listing reflects that.
What lot 38-01260229 actually says
The Ascension sermorelin listing publishes one certificate, and it is worth walking through because it is a reasonable example of the genre rather than a perfect one.
| Certificate field | Value |
|---|---|
| Laboratory | MZ Biolabs, 2102 N Country Club Rd, Tucson AZ 85716 |
| Lot | 38-01260229 |
| Date of analysis | February 7, 2026, signed February 13, 2026 |
| Purity | 99.79% |
| Measured quantity | 11.31 mg against a 10 mg label |
| Method | HPLC-UV-MS, four detected peaks |
| Analyst | Ken Pendarvis, ChE |
Two things stand out. The first is that the lab is named, with a street address, and so is the person who signed the report. That is a normal expectation in analytical work and an abnormal one in peptide retail.
The second is the measured quantity. The vial is labelled 10 mg and this lot assayed 11.31 mg, an overfill of about 13.1%. That is a property of lot 38-01260229 and not a promise about any vial that ships later, but it does change the arithmetic on the lot that was tested, which is covered in more detail on our sermorelin price breakdown.
We also checked the identity claim independently. The sequence printed on the certificate converts to YADAIFTNSYRKVLGQLSARKLLQDIMSR, twenty-nine residues with a C-terminal amide, which is canonical GHRH(1-29). PubChem CID 16132413 returns the same formula and mass the vendor lists, C149H246N44O42S at 3357.9 g/mol. The compound is what the label says it is.
What the certificate does not cover
This is the part most listings would rather you skimmed, and it is the reason this page exists.
The certificate reports purity and quantity. It does not report endotoxin, and it does not report sterility. For a lyophilised powder that buyers reconstitute and inject, those are not optional extras, they are the two tests most directly tied to what happens after the syringe.
The context makes it sharper. FDA's stated concern about this whole class of peptides, written into its Category 2 evaluations, is the "risk for immunogenicity" arising from "the potential for aggregation and peptide-related impurities". Purity by HPLC speaks to one half of that sentence. Nothing on this certificate speaks to the other half.
The honest way to write this is as a property of the batch: lot 38-01260229's certificate covers purity and quantity. It is not a claim that the vendor never tests for anything else, and it is not a claim that the material is contaminated. It is a statement about where the published evidence stops, and a reader is entitled to know that before deciding.
The claim a seller is not allowed to make
Research-supplier listings in the United States carry laboratory-use language, and they do not publish dosing charts, reconstitution protocols or outcome claims. That is not squeamishness. A seller that attaches a human-use claim to an unlabelled product has changed what it is selling in regulatory terms.
So the presence of a dosing schedule on a sales page is a red flag pointing the opposite way from the one buyers assume. It does not signal a more helpful vendor. It signals a vendor that has not read the rules it is operating under, which is a poor predictor of how carefully it handles anything else, including cold chain and lot control.
Secretagogue, not growth hormone
Readers arriving here from a training context usually want one question answered, so here it is directly: sermorelin is not HGH.
It is a synthetic twenty-nine amino acid peptide identical to the active N-terminal fragment of growth hormone releasing hormone. It binds the GHRH receptor on the anterior pituitary and prompts the pituitary to release the body's own growth hormone. That makes it a secretagogue, a compound that asks the gland to work, rather than an administration of recombinant growth hormone itself. Those are different purchases with different regulatory histories.
The evidence position deserves the same directness. PubMed returns 332 papers mentioning sermorelin, three with it in the title, and zero for sermorelin and anti-aging. ClinicalTrials.gov registers no trials naming the compound at all. The two title papers that are relevant are a 1999 BioDrugs review of use in children with idiopathic growth hormone deficiency (PMID 18031173) and a 2006 discussion of adult-onset growth hormone insufficiency (PMID 18046908). Neither is a body composition study.
That is the gap between the market and the literature, and it is worth holding onto while reading any listing. The same gap shows up across this category, which is why our muscle growth peptide overview spends more time on what has been measured than on what is being sold.
The regulatory record, stated correctly
A lot of competing pages get this backwards in one direction or the other, so the record is worth stating plainly.
Sermorelin was approved. Geref carried two applications from EMD Serono: NDA 019863, the diagnostic presentation at 0.05 mg per ampoule with submissions from May 1991, and NDA 020443, the therapeutic presentation at 0.5 mg and 1 mg per vial, originally approved on September 26, 1997. Both are listed as discontinued in Drugs@FDA, and the product record carries the Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. DailyMed returns no current label, because there is no marketed product to label.
Sermorelin is also absent from FDA's Category 2 bulk substances list, in every section. Ibutamoren mesylate sits on that list under both 503A and 503B. Ipamorelin acetate, GHRP-2 and GHRP-6 are there. Sermorelin is not, and that absence is why a prescription route through 503A compounding genuinely exists for this compound, which is set out on our sermorelin prescription page.
What the listing costs, per milligram
The pricing on the Ascension listing is straightforward once the arithmetic is done. List is $99.99, the site price is $72.00, and the code PEPTIDEDECK brings it to $36.00. On the 10 mg label that is $3.60 per milligram. On the 11.31 mg that lot 38-01260229 actually assayed, it is $3.18 per milligram. Quantity tiers of 3%, 5% and 10% come off list separately, and free shipping starts at $250.
The per milligram figure is only as good as the strength behind it, which is the argument for reading the certificate before the price. An unverified low price is arithmetic performed on a guess, a point we made at more length in the retatrutide source ranking and which applies here without modification.
Frequently asked questions
Is sermorelin legal to buy in the United States?
Sermorelin was an FDA-approved drug and is now discontinued, with no current US label. Because it was a component of an approved drug product, a compounding pharmacy can prepare it on a valid prescription under section 503A. Research suppliers sell it separately under laboratory-use terms, which is a different transaction with different expectations attached.
What is the fastest way to tell a real sermorelin listing from a fake one?
Ask for the certificate covering the batch currently shipping. A supplier holding its own stock can send it in minutes because the file is already on hand. An intermediary has to request it from someone else, and the delay is itself the answer.
Does 99.79% purity mean the vial is safe to inject?
No. Purity describes the proportion of the material that is the intended peptide. It says nothing about endotoxin or sterility, and lot 38-01260229's certificate does not report either. Those are separate tests, and a purity figure should not be read as covering them.
Why did the vial measure 11.31 mg when the label says 10 mg?
Lyophilised vials are commonly filled above the labelled amount to allow for handling losses. On this lot the measured content was 11.31 mg, an overfill of roughly 13.1%. That figure belongs to lot 38-01260229 and should not be assumed for any other batch.
Is sermorelin the same thing as HGH?
No. Sermorelin is GHRH(1-29) amide, a secretagogue that binds the GHRH receptor and prompts the pituitary to release the body's own growth hormone. Recombinant growth hormone is the hormone itself. They are different molecules with different regulatory histories and should not be treated as substitutes for one another.
This article is for educational purposes only and is not medical advice. Sermorelin was approved as Geref and is now discontinued, with no current US label; material sold by research suppliers is labeled for laboratory use only and not for human consumption. Speak with a qualified healthcare professional before making any decision involving peptides, injections, or off-label compounds.